<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073186</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6349</org_study_id>
    <nct_id>NCT04073186</nct_id>
  </id_info>
  <brief_title>Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia</brief_title>
  <official_title>Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-masked, dispensing clinical trial. A total of approximately 48 myopic and 32&#xD;
      hyperopic eligible subjects will be targeted to complete the study. Subjects will be fit in&#xD;
      the study lens, optimized if required and worn for approximately 2 weeks. Subjects will then&#xD;
      have a washout period of approximately 1 week and be refit in the lenses and be dispensed for&#xD;
      an additional 2 weeks of wear.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vision Scores</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Performance (logMAR)</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2).&#xD;
Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle</measure>
    <time_frame>Up to 2-Week Follow-up</time_frame>
    <description>Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>ACUVUE® OASYS with Transitions™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACUVUE® OASYS with Transitions™</intervention_name>
    <description>JJVC Marketed Contact Lens</description>
    <arm_group_label>ACUVUE® OASYS with Transitions™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects must satisfy all the following criteria to be enrolled in the&#xD;
             study:&#xD;
&#xD;
               1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and&#xD;
                  receive a fully executed copy of the form.&#xD;
&#xD;
               2. The subject must appear able and willing to adhere to the instructions set forth&#xD;
                  in this clinical protocol.&#xD;
&#xD;
               3. The subject must be between 40 and 70 years of age at the time of screening.&#xD;
&#xD;
               4. Subjects must own a wearable pair of spectacles if required for their distance&#xD;
                  vision.&#xD;
&#xD;
               5. The subject must be an adapted monovision soft contact lens wearer in both eyes&#xD;
                  (i.e., worn lenses a minimum of 2 days per week for at least 8 hours per wear&#xD;
                  day, for 1 month of more duration).&#xD;
&#xD;
               6. The subject's distance spherical equivalent refraction must be in the range of&#xD;
                  +3.50 D to -4.00 D in each eye.&#xD;
&#xD;
               7. The subject's refractive cylinder must be ≤1.00 D in each eye.&#xD;
&#xD;
               8. The subject's ADD power must be in the range of +0.75 D to +2.50 D.&#xD;
&#xD;
               9. The subject must have best corrected distance visual acuity of 20/20-3 or better&#xD;
                  in each eye.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Potential subjects who meet any of the following criteria will be excluded from&#xD;
             participating in the study:&#xD;
&#xD;
               1. Currently Pregnant or lactating.&#xD;
&#xD;
               2. Any active or ongoing systemic disease, autoimmune disease, or use of medication,&#xD;
                  which may interfere with contact lens wear. This may include, but not be limited&#xD;
                  to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's&#xD;
                  syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and&#xD;
                  immunosuppressive diseases or any infectious diseases (e.g., hepatitis,&#xD;
                  tuberculosis).&#xD;
&#xD;
               3. Use of any of the following medications within 1 week prior to enrollment: oral&#xD;
                  retinoid isotretinoin (e.g. Accutane), oral tetracyclines, oral phenothiazines&#xD;
                  (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), systemic&#xD;
                  steroids.&#xD;
&#xD;
               4. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy,&#xD;
                  PRK, LASIK, lid procedures, cataract surgery, retinal surgery,&#xD;
                  dacryocystorhinostomy, etc.).&#xD;
&#xD;
               5. Use of any ocular medication, with the exception of rewetting drops.&#xD;
&#xD;
               6. Participation in any contact lens or lens care product clinical trial within 7&#xD;
                  days prior to study enrollment.&#xD;
&#xD;
               7. Employee or immediate family member of an employee of clinical site (e.g.,&#xD;
                  Investigator, Coordinator, Technician).&#xD;
&#xD;
               8. Any known hypersensitivity or allergic reaction to OPTI-FREE® Puremoist® care&#xD;
                  cleaning solution, non-preserved rewetting drop solution or sodium fluorescein.&#xD;
&#xD;
               9. History of herpetic keratitis.&#xD;
&#xD;
              10. Entropion, ectropion, chalazia, glaucoma, history of recurrent corneal erosions.&#xD;
&#xD;
              11. A history of amblyopia, strabismus or binocular vision abnormality.&#xD;
&#xD;
              12. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization,&#xD;
                  corneal staining, tarsal abnormalities or bulbar injection, or any other corneal&#xD;
                  or ocular abnormalities which would contraindicate contact lens wear.&#xD;
&#xD;
              13. Any ocular infection or inflammation.&#xD;
&#xD;
              14. Any ocular abnormality that may interfere with contact lens wear.&#xD;
&#xD;
              15. Any active or ongoing ocular or systemic allergies that may interfere with&#xD;
                  contact lens wear.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VRC-East</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Eyecare</name>
      <address>
        <city>Raytown</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Vision Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Reserve Vision Care, Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David W. Ferris &amp; Associates</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <results_first_submitted>March 19, 2021</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04073186/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 91 subjects were enrolled in this study. Of those enrolled, 86 subjects were dispensed a least one study lens while 5 subjects failed to meet all eligibility criteria. Of those dispensed, 79 subjects completed the study, while 7 were discontinued.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Test</title>
          <description>Subjects received the Test lens throughout the study. Subjects wore the Test lens twice for a period of approximately 2 weeks each.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Wearing Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Time required to complete last two study visits exceeds study deadline</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lens Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Visual Response due to Test Article</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Wearing Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test</title>
          <description>Subjects received the Test lens throughout the study. Subjects wore the Test lens twice for a period of approximately 2 weeks each.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vision Scores</title>
        <description>Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (First Wearing Cycle)</title>
            <description>All subjects that wore the Test lens during the first wearing cycle</description>
          </group>
          <group group_id="O2">
            <title>Test (Second Wearing Cycle)</title>
            <description>All subjects that wore the Test lens during the second wearing cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Vision Scores</title>
          <description>Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.38" spread="19.700"/>
                    <measurement group_id="O2" value="56.19" spread="23.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority of the First wearing Cycle was concluded if the lower confidence limit of leastsquare mean as greater than 32.</non_inferiority_desc>
            <param_type>Least-square Mean</param_type>
            <param_value>59.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.6</ci_lower_limit>
            <ci_upper_limit>64.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Performance (logMAR)</title>
        <description>Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2).&#xD;
Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major prtocol deviation impacting a primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Test (First Wearing Cycle)</title>
            <description>All subjects that wore the Test lens during the first wearing cycle</description>
          </group>
          <group group_id="O2">
            <title>Test (Second Wearing Cycle)</title>
            <description>All subjects that wore the Test lens during the second wearing cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Performance (logMAR)</title>
          <description>Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2).&#xD;
Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.</description>
          <population>Subjects that completed all study visits without a major prtocol deviation impacting a primary endpoint</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Distance (4 Meter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.097"/>
                    <measurement group_id="O2" value="-0.08" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate (64 CM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.096"/>
                    <measurement group_id="O2" value="-0.03" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Near (40 CM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.085"/>
                    <measurement group_id="O2" value="0.02" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority of the Test lens was concluded if the upper confidence limit of least-square mean was below the pre-defined threshold 0.10 logMAR.</non_inferiority_desc>
            <param_type>Least-square Mean</param_type>
            <param_value>-0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0191</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.124</ci_lower_limit>
            <ci_upper_limit>-0.044</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Intermediate (64 CM)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority of the Test lens was concluded if the upper confidence limit of least-square mean was below the pre-defined threshold 0.17 logMAR.</non_inferiority_desc>
            <param_type>Least-square Mean</param_type>
            <param_value>-0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0191</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.068</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Near (40 CM)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority of the Test lens was concluded if the upper confidence limit of least-square mean was below the pre-defined threshold 0.17 logMAR</non_inferiority_desc>
            <param_type>Least-square Means</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0191</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle</title>
        <description>Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>Up to 2-Week Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (First Wearing Cycle)</title>
            <description>All subjects that wore the Test lens during the first wearing cycle</description>
          </group>
          <group group_id="O2">
            <title>Test (Second Wearing Cycle)</title>
            <description>All subjects that wore the Test lens during the second wearing cycle</description>
          </group>
        </group_list>
        <measure>
          <title>CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle</title>
          <description>Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.38" spread="19.700"/>
                    <measurement group_id="O2" value="56.19" spread="23.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority of the Test lens at 4-week followup compared to it at 2-week follow-up will beconcluded if the lower confidence limit of leastsquare mean difference is greater than 0.</non_inferiority_desc>
            <param_type>Least-square Mean Difference</param_type>
            <param_value>-4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>LSM difference was calculated as Second Wearing Cycle minus First Wearing Cycle</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 1 month per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Subjects received the Test lens throughout the study. Subjects wore the Test lens twice for a period of approximately 2 weeks each.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Not related to study treatment, subject was discontinued and AE was resolved by the end of the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Karkkainen- Sr. Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>1-800-843-2020</phone>
      <email>TKarkkai@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

